Focus on achieving better precision in cancer diagnosis and treatment, targeting only affected cells will fuel demand for cancer RNA expressions
Focus on achieving better precision in cancer diagnosis and treatment, targeting only affected cells will fuel demand for cancer RNA expressions
Fact.MR, Rockville MD: Market research firm Fact.MR ongoing study presents positive outlook on the cancer RNA expression market. The World Health Organization (WHO) identifies cancer as the second-leading cause of death globally, accounting for about 10 million deaths each year. With the prevalence of cancer rising consistently, analysis of RNA expression is gaining momentum.
Differential RNA expression analysis can offer insights into molecular mechanisms and molecular pathways regulating cell fate and ultimately disease progression. With focus on cancer research increasing, the interest on cancer RNA expression is piqued. Against this backdrop, Fact MR has forecast positive growth on cards for cancer RNA expression market.
It studies opportunities for various sequencing techniques including targeted RNA sequencing, small RNA and miRNA sequencing, transcriptome sequencing, and PCR sequencing. Recent advances in next-generation sequencing and in real-time PCR throughput has revolutionized the way in which differential gene expression is analyzed.
The report identifies aforementioned advancements as crucial events paving way for the overall expansion of the market. With focus on timely and accurate diagnosis higher than ever before, Fact MR projects the demand for cancer RNA expressions to surge in the coming years.
“Side-effects commonly associated with chemotherapy and radiotherapy have been improving prospects for cancer RNA expression uptake. Unlike chemotherapy, cancer RNA expressions target has made it possible to target only mutated cells, minimizing the risk commonly associated with cancer treatment. This factor has been presenting a conducive environment for growth in response to the consistently rising demand for precise cancer treatment and diagnosis,” said a lead analyst at Fact MR.
Request a report sample to gain detailed insights at https://www.factmr.com/connectus/sample?flag=S&rep_id=3149
Key Takeaways from Fact.MR’s Cancer RNA Expression Market Report
- North America is forecast to remain dominant backed by rising cancer prevalence
- Backed by presence of some of the leading players, the U.S. will continue accounting for maximum demand in North America
- Focus towards reducing cancer burden will drive growth in the U.K.
- As per German Cancer Research Center, more than 450,000 people are diagnosed with cancer each year in Germany, making it a potential market for cancer RNA expression
- Investments in cancer research will continue driving growth in China
Cancer RNA Expression Market – Prominent Drivers
- Studies undertaken to strengthen the cancer RNA expression pipeline will remain a chief growth driver
- Possibilities of minimizing side-effects commonly associated with chemotherapy to drive cancer RNA expression uptake
- Initiatives undertaken to reduce cancer burden will continue driving the market
Cancer RNA Expression Market – Key Restraints
- Lower commercial availability will remain a chief restraint
- Lack of awareness is expected to limit growth especially in underdeveloped countries
Discover more about the cancer RNA expression market with figures data tables and table of contents. You can also find detailed market segmentation at https://www.factmr.com/report/3149/cancer-rna-expression-market
Competitive Landscape
Some of the leading players operating in the market are Thermo Fisher Scientific, Illumina Inc., Pacific Biosciences of California Inc., PerkinElmer Inc., QIAGEN N. V., GATC Biotech AG, Macrogen, Inc., Oxford Nanopore Technologies Ltd., Roche Holding AG, Eurofins Scientific among others.
Companies operating in the market have been increasingly focusing on research and development. Besides this, some of the market players have been focusing on commercializing their product portfolio to create a brand awareness. For instance, in September 2020, 10x Genomics made Chromium Single Cell Multiome ATAC + Gene Expression solutions commercially available in the market.
More Insights into Cancer RNA Expression Market
In its latest report, Fact.MR offers unbiased analysis of the global cancer RNA expression market. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of sequencing type (targeted RNA sequencing, small RNA and miRNA sequencing, transcriptome sequencing, and PCR sequencing) and end user (diagnostic laboratories, hospitals, specialty clinics, and academic research institutes) across seven regions (North America, Latin America, Western Europe, Eastern Europe, Japan, Asia Pacific excluding Japan, and Middle East & Africa)
Request more information about Report Methodology
https://www.factmr.com/connectus/sample?flag=RM&rep_id=3149
Explore Fact.MR’s Coverage on the Healthcare Domain
Blood Cancer Diagnostics Market: A recent study by Fact.MR on the blood cancer diagnostics market offers a 10-year forecast for 2017 to 2027. The study analyzes key trends that are currently determining the growth of the market. This report covers vital dynamics, including drivers, restraints, and opportunities for leading market players along with key stakeholders and emerging players.
Lung Cancer Diagnostics Market: Fact.MR’s extensive coverage on the lung cancer diagnostics market offers in-depth insights about the prominent growth dynamics that are likely to aid expansion of prospects in the near future. Data has been presented in the form of key segments across prominent geographies, along with important information concerning key manufacturers operating within the landscape.
Ovarian Cancer Diagnostics Market: The global ovarian cancer diagnostics market study published by Fact.MR offers an unbiased analysis of the prominent drivers, opportunities and trends expected to shape future expansion outlook. The report provides a comprehensive assessment on the prominent segments and geographies which are likely to benefit market players in forthcoming years.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
Sudip Saha
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583